Movement Alert｜Argenx SE Falls 3.46% in Pre-Market Trading, Q3 EPS Slightly Misses Expectations Despite Sales Beat

Market Focus10-22

On October 22, Argenx SE fell 3.46% in Pre-Market Trading, trading at $856.34, with turnover of $415,000.

The move was earnings-driven. The company reported third-quarter EPS of $7.80, slightly below the consensus estimate of $7.83, while sales reached $1.751 billion, above the $1.664 billion expected.

Recent sentiment had already been shaped by pipeline developments, including positive phase 3 data for Vyvgart Hytrulo in autoimmune myositis, the discontinuation of a late-stage Sjogren's disease trial, and phase 2 progress in celiac disease. Against that backdrop, the small earnings miss appears to have been the direct trigger for the pre-market pressure despite stronger revenue.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment